

International Textbook of Diabetes Mellitus, 4th Ed., Chapter 5 - Pancreatic Morphology in Normal and Diabetic States

References:

1. Rahier J, Goebbels RM, Henquin JC: Cellular composition of the human diabetic pancreas. *Diabetologia* 1983;24:366–371.
2. Ogilvie RF: A quantitative estimation of pancreatic islet tissue. *QJM* 1937;30:287–300.
3. Slack JM: Developmental biology of the pancreas. *Development* 1995;121:1569–1580.
4. von Mering J, Minkowski O: Diabetes mellitus nach Pankreas extirpation. *Archiv für experimentelle Pathologie und Pharmakologie* 1890;26:371–378.
5. Stefan Y, Orci L, Malaisse-Lagae F, et al.: Quantitation of endocrine cell content in the pancreas of nondiabetic and diabetic humans. *Diabetes* 1982;31:694–700.
6. Hellman B: The frequency distribution of the number and volume of the islets Langerhans in man. I. Studies on non-diabetic adults. *Acta Societatis Medicorum Upsaliensis* 1959;64:432–460.
7. Lifson N, Kramlinger KG, Mayrand RR, Lender EJ: Blood flow to the rabbit pancreas with special reference to the islets of Langerhans. *Gastroenterology* 1980;79:466–473.
8. Groger G, Laver P: Exocrine pancreatic function in diabetes mellitus. *European Journal of Gastroenterology & Hepatology* 1995;7: 740–746.
9. Greenberg GR, McCloy RF, Adrian TE, et al.: Inhibition of pancreas and gallbladder by pancreatic polypeptide. *Lancet* 1978;2: 1280–1282.
10. Zajtchuk R, Amato JJ, Paloyan E, Baker RJ: Inhibition of pancreatic exocrine secretion by glucagon. *Surgical Forum* 1967;18:410–411.
11. Orci L: The insulin factory: a tour of the plant surroundings and a visit to the assembly line. The Minkowski lecture 1973 revisited. *Diabetologia* 1985;28:528–546.
12. Lane MA: The cytological characters of the areas of Langerhans. *American Journal of Anatomy* 1907;7:409–422.
13. Brissova M, Fowler MJ, Nicholson WE, et al.: Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy. *Journal of Histochemistry & Cytochemistry* 2005;53:1087–1097.
14. Cabrera O, Berman DM, Kenyon NS, et al.: The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. *PNAS* 2006;103:2334–2339.
15. Butler AE, Janson J, Bonner-Weir S, et al.: Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. *Diabetes* 2003;52:102–110.
16. Rahier J, Guiot Y, Goebbels RM, et al.: Pancreatic beta-cell mass in European subjects with type 2 diabetes. *Diabetes, Obesity and Metabolism* 2008;10(Suppl 4):32–42.
17. Jurgens CA, Toukatly MN, Fligner CL, et al.: Beta-cell loss and beta-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. *American Journal of Pathology* 2011;178: 2632–2640.
18. Bosco D, Armanet M, Morel P, et al.: Unique arrangement of alpha- and beta-cells in human islets of Langerhans. *Diabetes* 2010;59:1202–1210.

19. Baetens D, Malaisse-Lagae F, Perrelet A, Orci L: Endocrine pancreas: three-dimensional reconstruction shows two types of islets of langerhans. *Science* 1979;206:1323–1325.
20. Kahn SE, D'Alessio DA, Schwartz MW, et al.: Evidence of co-secretion of islet amyloid polypeptide and insulin by beta-cells. *Diabetes* 1990;39:634–638.
21. Munger BL: The histology, cytochemistry and ultrastructure of pancreatic islet A-cells. In: Lefebvre PJ, Unger RH (eds.) *Glucagon*. Oxford/New York: Pergamon, 1972, p. 7.
22. Taborsky GJ, Jr: Evidence of a paracrine role for pancreatic somatostatin in vivo. *American Journal of Physiology - Endocrinology and Metabolism* 1983;245:E598–E603.
23. Wang X, Zielinski MC, Misawa R, et al.: Quantitative analysis of pancreatic polypeptide cell distribution in the human pancreas. *PloS ONE* 2013;8:e55501.
24. Schwartz TW: Pancreatic polypeptide: a unique model for vagal control of endocrine systems. *Journal of the Autonomic Nervous System* 1983;9:99–111.
25. Asakawa A, Inui A, Yuzuriha H, et al.: Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. *Gastroenterology* 2003;124:1325–1336.
26. Wierup N, Svensson H, Mulder H, Sundler F: The ghrelin cell: a novel developmentally regulated islet cell in the human pancreas. *Regulatory Peptides* 2002;107:63–69.
27. Reimer MK, Pacini G, Ahrén B: Dose-dependent inhibition by ghrelin of insulin secretion in the mouse. *Endocrinology* 2003;144: 916–921.
28. Tong J, Prigeon RL, Davis HW, et al.: Ghrelin suppresses glucose stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. *Diabetes* 2010;59:2145–2151.
29. Jansson L, Hellerstrom C: Stimulation by glucose of the blood flow to the pancreatic islets of the rat. *Diabetologia* 1983;25:45–50.
30. Bonner-Weir S, Orci L: New perspectives on the microvasculature of the islets of Langerhans in the rat. *Diabetes* 1982;31:883–889.
31. Henderson JR, Daniel PM: A comparative study of the portal vessels connecting the endocrine and exocrine pancreas, with a discussion of some functional implications. *Quarterly Journal of Experimental Physiology* 1979;64:267–275.
32. Nyman LR, Wells KS, Head WS, et al.: Real-time, multidimensional in vivo imaging used to investigate blood flow in mouse pancreatic islets. *Journal of Clinical Investigation* 2008;118:3790–3797.
33. Stagner JI, Samols E, Bonner-Weir S: beta---alpha---delta pancreatic islet cellular perfusion in dogs. *Diabetes* 1988;37:1715–1721.
34. Murakami T, Fujita T, Miyake T, et al.: The insulo-acinar portal and insulo-venous drainage systems in the pancreas of the mouse, dog, monkey and certain other animals: a scanning electron microscopic study of corrosion casts. *Archives of Histology and Cytology* 1993;56:127–147.
35. Stagner JI, Samols E: The vascular order of islet cellular perfusion in the human pancreas. *Diabetes* 1992;41:93–97.
36. Korpos E, Kadri N, Kappelhoff R, et al.: The peri-islet basement membrane, a barrier to infiltrating leukocytes in type 1 diabetes in mouse and human. *Diabetes* 2013;62:531–542.
37. Henderson JR, Moss MC: A morphometric study of the endocrine and exocrine capillaries of the pancreas. *Quarterly Journal of Experimental Physiology* 1985;70:347–356.

38. Hart TK, Pino RM: Pseudoislet vascularization. Induction of diaphragm-fenestrated endothelia from the hepatic sinusoids. *Laboratory Investigation* 1986;54:304–313.
39. Lammert E, Cleaver O, Melton D: Induction of pancreatic differentiation by signals from blood vessels. *Science* 2001;294:564–567.
40. Nikolova G, Jabs N, Konstantinova I, et al.: The vascular basement membrane: a niche for insulin gene expression and beta cell proliferation. *Developmental Cell* 2006;10:397–405.
41. Johansson M, Mattsson G, Andersson A, et al.: Islet endothelial cells and pancreatic beta-cell proliferation: studies in vitro and during pregnancy in adult rats. *Endocrinology* 2006;147:2315–2324.
42. Irving-Rodgers HF, Ziolkowski AF, Parish CR, et al.: Molecular composition of the peri-islet basement membrane in NOD mice: a barrier against destructive insulinitis. *Diabetologia* 2008;51: 1680–1688.
43. Virtanen I, Banerjee M, Palgi J, et al.: Blood vessels of human islets of Langerhans are surrounded by a double basement membrane. *Diabetologia* 2008;51:1181–1191.
44. Otonkoski T, Banerjee M, Korsgren O, et al.: Unique basement membrane structure of human pancreatic islets: implications for beta-cell growth and differentiation. *Diabetes, Obesity and Metabolism* 2008;10(S4):119–127.
45. Johansson A, Lau J, Sandberg M, et al.: Endothelial cell signalling supports pancreatic beta cell function in the rat. *Diabetologia* 2009;52:2385–2394.
46. Stendahl JC, Kaufman DB, Stupp SI: Extracellular matrix in pancreatic islets: relevance to scaffold design and transplantation. *Cell Transplantation* 2009;18:1–12.
47. Åhrén B: Autonomic regulation of islet hormone secretion—implications for health and disease. *Diabetologia* 2000;43:393–410.
48. Chiu YC, Hua TE, Fu YY, et al.: 3-D imaging and illustration of the perfusive mouse islet sympathetic innervation and its remodelling in injury. *Diabetologia* 2012;55:3252–3261.
49. Rodriguez-Diaz R, Abdulreda MH, Formoso AL, et al.: Innervation patterns of autonomic axons in the human endocrine pancreas. *Cell Metabolism* 2011;14:45–54.
50. Ravier MA, Guldenagel M, Charollais A, et al.: Loss of connexin 36 channels alters beta-cell coupling, islet synchronization of glucose-induced Ca²⁺ and insulin oscillations, and basal insulin release. *Diabetes* 2005;54:1798–1807.
51. Xu E, Kumar M, Zhang Y, et al.: Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system. *Cell Metabolism* 2006;3:47–58.
52. Braun M, Ramracheya R, Bengtsson M, et al.: Gamma-aminobutyric acid (GABA) is an autocrine excitatory transmitter in human pancreatic beta-cells. *Diabetes* 2010;59:1694–1701.
53. Olerud J, Mokhtari D, Johansson M, et al.: Thrombospondin-1: an islet endothelial cell signal of importance for beta-cell function. *Diabetes* 2011;60:1946–1954.
54. Bosco D, Meda P, Halban PA, Rouiller DG: Importance of cell-matrix interactions in rat islet beta-cell secretion in vitro: role of alpha6beta1 integrin. *Diabetes* 2000;49:233–243.
55. Bonner-Weir S: Beta-cell turnover: its assessment and implications. *Diabetes* 2001;50(Suppl 1):S20–24.
56. Rankin MM, Kushner JA: Adaptive beta-cell proliferation is severely restricted with advanced age. *Diabetes* 2009;58: 1365–1372.

57. Meier JJ, Butler AE, Saisho Y, et al.: Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. *Diabetes* 2008;57:1584–1594.
58. Cnop M, Hughes SJ, Igoillo-Esteve M, et al.: The long lifespan and low turnover of human islet beta cells estimated by mathematical modelling of lipofuscin accumulation. *Diabetologia* 2010;53: 321–330.
59. Kloppel G, Lohr M, Habich K, et al.: Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. *Survey and Synthesis of Pathology Research* 1985;4:110–125.
60. Parsons JA, Brelje TC, Sorenson RL: Adaptation of islets of Langerhans to pregnancy: increased islet cell proliferation and insulin secretion correlates with the onset of placental lactogen secretion. *Endocrinology* 1992;130:1459–1466.
61. Butler AE, Cao-Minh L, Galasso R, et al.: Adaptive changes in pancreatic beta cell fractional area and beta cell turnover in human pregnancy. *Diabetologia* 2010;53:2167–2176.
62. Hull RL, Kodama K, Utzschneider KM, et al.: Dietary-fat-induced obesity in mice results in beta cell hyperplasia but not increased insulin release: evidence for specificity of impaired beta cell adaptation. *Diabetologia* 2005;48:1350–1358.
63. Lee HC, Bonner-Weir S, Weir GC, Leahy JL: Compensatory adaptation to partial pancreatectomy in the rat. *Endocrinology* 1989;124:1571–1575.
64. Menge BA, Tannapfel A, Belyaev O, et al.: Partial pancreatectomy in adult humans does not provoke beta-cell regeneration. *Diabetes* 2008;57:142–149.
65. Hull RL, Andrikopoulos S, Verchere CB, et al.: Increased dietary fat promotes islet amyloid formation and β -cell secretory dysfunction in a transgenic mouse model of islet amyloid. *Diabetes* 2003;52:372–379.
66. Ahren B, Gudbjartsson T, Al-Amin AN, et al.: Islet perturbations in rats fed a high-fat diet. *Pancreas* 1999;18:75–83.
67. Ahren B, Simonsson E, Scheurink AJ, et al.: Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet induced insulin resistance in C57BL/6J mice. *Metabolism* 1997; 46:97–106.
68. Gepts W: Pathologic anatomy of the pancreas in juvenile diabetes mellitus. *Diabetes* 1965;14:619–633.
69. Maclean N, Ogilvie RF: Observations on the pancreatic islet tissue of young diabetic subjects. *Diabetes* 1959;8:83–91.
70. Foulis AK, Stewart JA: The pancreas in recent-onset type 1 (insulin-dependent) diabetes mellitus: insulin content of islets, insulinitis and associated changes in the exocrine acinar tissue. *Diabetologia* 1984;26:456–461.
71. Willcox A, Richardson SJ, Bone AJ, et al.: Analysis of islet inflammation in human type 1 diabetes. *Clinical & Experimental Immunology* 2009;155:173–181.
72. Coppieters KT, Dotta F, Amirian N, et al.: Demonstration of islet-autoreactive CD8 T cells in insulinitic lesions from recent onset and long-term type 1 diabetes patients. *Journal of Experimental Medicine* 2012;209:51–60.
73. Miyazaki A, Hanafusa T, Yamada K, et al.: Predominance of T lymphocytes in pancreatic islets and spleen of pre-diabetic non-obese diabetic (NOD) mice: a longitudinal study. *Clinical & Experimental Immunology* 1985;60:622–630.
74. Like AA, Butler L, Williams RM, et al.: Spontaneous autoimmune diabetes mellitus in the BB rat. *Diabetes* 1982;31:7–13.
75. Atkinson MA, Gianani R: The pancreas in human type 1 diabetes: providing new answers to age-old questions. *Current Opinion in Endocrinology, Diabetes, and Obesity* 2009;16:279–285.

76. Foulis AK, Liddle CN, Farquharson MA, et al.: The histopathology of the pancreas in type 1 (insulin-dependent) diabetes mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. *Diabetologia* 1986;29:267–274.
77. Greenbaum CJ, Beam CA, Boulware D, et al.: Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. *Diabetes* 2012;61:2066–2073.
78. Sosenko JM, Skyler JS, Herold KC, Palmer JP: The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial-type 1. *Diabetes* 2012;61:1331–1337.
79. Meier JJ, Bhushan A, Butler AE, et al.: Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? *Diabetologia* 2005;48:2221–2228.
80. Keenan HA, Sun JK, Levine J, et al.: Residual insulin production and pancreatic β -cell turnover after 50 years of diabetes: Joslin Medalist Study. *Diabetes* 2010;59:2846–2853.
81. Meier JJ, Lin JC, Butler AE, et al.: Direct evidence of attempted beta cell regeneration in an 89-year-old patient with recent-onset type 1 diabetes. *Diabetologia* 2006;49:1838–1844.
82. Butler AE, Galasso R, Meier JJ, et al.: Modestly increased beta cell apoptosis but no increased beta cell replication in recent-onset type 1 diabetic patients who died of diabetic ketoacidosis. *Diabetologia* 2007;50:2323–2331.
83. DCCT: Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. *Annals of Internal Medicine* 1998;128:517–523.
84. Couri CE, Oliveira MC, Stracieri AB, et al.: C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. *JAMA* 2009;301:1573–1579.
85. Muller WA, Faloon GR, Aguilar-Parada E, Unger RH: Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. *New England Journal of Medicine* 1970;283: 109–115.
86. Bolli GB, Tsalikian E, Haymond MW, et al.: Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine interactions. *Journal of Clinical Investigation* 1984;73:1532–1541.
87. Zhou H, Tran PO, Yang S, et al.: Regulation of alpha-cell function by the beta-cell during hypoglycemia in Wistar rats: the "switch-off" hypothesis. *Diabetes* 2004;53:1482–1487.
88. Munding TO, Mei Q, Figlewicz DP, et al.: Impaired glucagon response to sympathetic nerve stimulation in the BB diabetic rat: effect of early sympathetic islet neuropathy. *American Journal of Physiology—Endocrinology and Metabolism* 2003;285: E1047–E1054.
89. Taborsky GJ, Jr, Mei Q, Hackney DJ, et al.: Loss of islet sympathetic nerves and impairment of glucagon secretion in the NOD mouse: relationship to invasive insulinitis. *Diabetologia* 2009;52:2602–2611.
90. Taborsky GJ, Jr, Munding TO: Minireview: The role of the autonomic nervous system in mediating the glucagon response to hypoglycemia. *Endocrinology* 2012;153:1055–1062.

91. Weiss L, Slavin S, Reich S, et al.: Induction of resistance to diabetes in non-obese diabetic mice by targeting CD44 with a specific monoclonal antibody. *PNAS* 2000;97:285–290.
92. Bollyky PL, Bogdani M, Bollyky JB, et al.: The role of hyaluronan and the extracellular matrix in islet inflammation and immune regulation. *Current Diabetes Reports* 2012;12:471–480.
93. Ziolkowski AF, Popp SK, Freeman C, et al.: Heparan sulfate and heparanase play key roles in mouse beta cell survival and autoimmune diabetes. *Journal of Clinical Investigation* 2012;122:132–141.
94. Sorokin L: The impact of the extracellular matrix on inflammation. *Nature Reviews Immunology* 2010;10:712–723.
95. Clark A, Wells CA, Buley ID, et al.: Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis -- quantitative changes in the pancreas in type-2 diabetes. *Diabetes Research* 1988;9:151–159.
96. Opie EL: The relation of diabetes mellitus to lesions of the pancreas: hyaline degeneration of the islets of Langerhans. *Journal of Experimental Medicine* 1901;5:527–540.
97. Maclean N, Ogilvie RF: Quantitative estimation of the pancreatic islet tissue in diabetic subjects. *Diabetes* 1955;4:367–376.
98. Yoon KH, Ko SH, Cho JH, et al.: Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. *Journal of Clinical Endocrinology & Metabolism* 2003;88:2300–2308.
99. Howarth FC, Al Kitbi MK, Hameed RS, Adeghate E: Pancreatic peptides in young and elderly Zucker type 2 diabetic fatty rats. *Journal of the Pancreas* 2011;12:567–573.
100. Makino H, Matsushima Y, Kanatsuka A, et al.: Changes in pancreatic somatostatin content in spontaneously diabetic mice, as determined by radioimmunoassay and immunohistochemical methods. *Endocrinology* 1979;104:243–247.
101. Patel YC, Cameron DP, Stefan Y, et al.: Somatostatin: widespread abnormality in tissues of spontaneously diabetic mice. *Science* 1977;198:930–931.
102. Like AA, Chick WL: Studies in the diabetic mutant mouse. II. Electron microscopy of pancreatic islets. *Diabetologia* 1970;6:216–242.
103. Nakamura M, Kitamura H, Konishi S, et al.: The endocrine pancreas of spontaneously diabetic db/db mice: microangiopathy as revealed by transmission electron microscopy. *Diabetes Research and Clinical Practice* 1995;30:89–100.
104. Mizuno A, Noma Y, Kuwajima M, et al.: Changes in islet capillary angioarchitecture coincide with impaired B-cell function but not with insulin resistance in male Otsuka-Long-Evans-Tokushima fatty rats: dimorphism of the diabetic phenotype at an advanced age. *Metabolism* 1999;48:477–483.
105. Tikellis C, Wookey PJ, Candido R, et al.: Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat. *Diabetes* 2004;53:989–997.
106. Li X, Zhang L, Meshinchi S, et al.: Islet microvasculature in islet hyperplasia and failure in a model of type 2 diabetes. *Diabetes* 2006;55:2965–2973.
107. Shao J, Iwashita N, Ikeda F, et al.: Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on beta-cell function and morphology in db/db mice. *Biochemical and Biophysical Research Communications* 2006;344:1224–1233.

108. Masuyama T, Komeda K, Hara A, et al.: Chronological characterization of diabetes development in male spontaneously diabetic Torii rats. *Biochemical and Biophysical Research Communications* 2004;314:870–877.
109. Kohnert KD, Axcrone UM, Hehmke B, et al.: Islet neuronal abnormalities associated with impaired insulin secretion in type 2 diabetes in the Chinese hamster. *Regulatory Peptides* 1999;82: 71–79.
110. Westermark P: Quantitative studies on amyloid in the islets of Langerhans. *Uppsala Journal of Medical Sciences* 1972;77:91–94.
111. Hayden MR, Karuparthi PR, Habibi J, et al.: Ultrastructural islet study of early fibrosis in the Ren2 rat model of hypertension. Emerging role of the islet pancreatic pericyte-stellate cell. *Journal of the Pancreas* 2007;8:725–738.
112. Donath MY, Schumann DM, Faulenbach M, et al.: Islet inflammation in type 2 diabetes: from metabolic stress to therapy. *Diabetes Care* 2008;31(S2):S161–S164.
113. Solomon SS, Duckworth WC, Jallepalli P, et al.: The glucose intolerance of acute pancreatitis: hormonal response to arginine. *Diabetes* 1980;29:22–26.
114. Bank S, Marks IN, Vinik AI: Clinical and hormonal aspects of pancreatic diabetes. *American Journal of Gastroenterology* 1975; 64:13–22.
115. Noel RA, Braun DK, Patterson RE, Bloomgren GL: Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. *Diabetes Care* 2009;32:834–838.
116. FitzSimmons SC: The changing epidemiology of cystic fibrosis. *Journal of Pediatrics* 1993;122:1–9.
117. Moran A, Hardin D, Rodman D, et al.: Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. *Diabetes Research and Clinical Practice* 1999;45:61–73.
118. Lanng S, Thorsteinsson B, Pociot F, et al.: Diabetes mellitus in cystic fibrosis: genetic and immunological markers. *Acta Paediatrica* 1993;82:150–154.
119. Bismuth E, Laborde K, Taupin P, et al.: Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis. *Journal of Pediatrics* 2008;152:540–545.
120. Elder DA, Wooldridge JL, Dolan LM, D'Alessio DA: Glucose tolerance, insulin secretion, and insulin sensitivity in children and adolescents with cystic fibrosis and no prior history of diabetes. *Journal of Pediatrics* 2007;151:653–658.
121. Kopito LE, Shwachman H: The pancreas in cystic fibrosis: chemical composition and comparative morphology. *Pediatric Research* 1976;10:742–749.
122. Abdul-Karim FW, Dahms BB, Velasco ME, Rodman HM: Islets of Langerhans in adolescents and adults with cystic fibrosis. A quantitative study. *Archives of Pathology & Laboratory Medicine* 1986;110:602–606.
123. Couce M, O'Brien TD, Moran A, et al.: Diabetes mellitus in cystic fibrosis is characterized by islet amyloidosis. *Journal of Clinical Endocrinology & Metabolism* 1996;81:1267–1272.
124. Unger RH, Grundy S: Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. *Diabetologia* 1985;28:119–121.
125. Leahy JL, Cooper HE, Weir GC: Impaired insulin secretion associated with near normoglycemia. Study in normal rats with 96-h in vivo glucose infusions. *Diabetes* 1987;36:459–464.
126. Robertson RP, Zhang HJ, Pyzdrowski KL, Walseth TF: Preservation of insulin mRNA levels and insulin secretion in HIT cells by avoidance of chronic

- exposure to high glucose concentrations. *Journal of Clinical Investigation* 1992;90:320–325.
127. Maedler K, Spinas GA, Lehmann R, et al.: Glucose induces beta-cell apoptosis via upregulation of the Fas receptor in human islets. *Diabetes* 2001;50:1683–1690.
 128. Kim WH, Lee JW, Suh YH, et al.: Exposure to chronic high glucose induces beta-cell apoptosis through decreased interaction of glucokinase with mitochondria: downregulation of glucokinase in pancreatic beta-cells. *Diabetes* 2005;54:2602–2611.
 129. Minn AH, Hafele C, Shalev A: Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces beta-cell apoptosis. *Endocrinology* 2005;146: 2397–2405.
 130. Efanova IB, Zaitsev SV, Zhivotovsky B, et al.: Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca^{2+} concentration. *The Journal of Biological Chemistry* 1998;273:33501–33507.
 131. Federici M, Hribal M, Perego L, et al.: High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. *Diabetes* 2001;50:1290–1301.
 132. Piro S, Anello M, Di Pietro C, et al.: Chronic exposure to free fatty acids or high glucose induces apoptosis in rat pancreatic islets: possible role of oxidative stress. *Metabolism* 2002;51:1340–1347.
 133. Kaiser N, Corcos AP, Sarel I, Cerasi E: Monolayer culture of adult rat pancreatic islets on extracellular matrix: modulation of B-cell function by chronic exposure to high glucose. *Endocrinology* 1991; 129:2067–2076.
 134. Gleason CE, Gonzalez M, Harmon JS, Robertson RP: Determinants of glucose toxicity and its reversibility in the pancreatic islet beta-cell line, HIT-T15. *American Journal of Physiology - Endocrinology and Metabolism* 2000;279:E997–E1002.
 135. Hoorens A, Van de Casteele M, Kloppel G, Pipeleers D: Glucose promotes survival of rat pancreatic beta cells by activating synthesis of proteins which suppress a constitutive apoptotic program. *Journal of Clinical Investigation* 1996;98:1568–1574.
 136. Woerner CA: Studies on the islands of Langerhans after continuous injection of dextrose. *The Anatomical Record* 1939;71:22–57.
 137. Bonner-Weir S, Deery D, Leahy JL, Weir GC: Compensatory growth of pancreatic beta-cells in adult rats after short-term glucose infusion. *Diabetes* 1989;38:49–53.
 138. Steil GM, Trivedi N, Jonas JC, et al.: Adaptation of beta-cell mass to substrate oversupply: enhanced function with normal gene expression. *American Journal of Physiology - Endocrinology and Metabolism* 2001;280:E788–E796.
 139. Sako Y, Grill VE: A 48-hour lipid infusion in the rat time dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation. *Endocrinology* 1990;127:1580–1589.
 140. Zhou YP, Grill VE: Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. *Journal of Clinical Investigation* 1994;93:870–876.
 141. Unger RH: Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. *Diabetes* 1995;44: 863–870.

142. Shimabukuro M, Zhou YT, Levi M, Unger RH: Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. *PNAS* 1998;95:2498–2502.
143. Maedler K, Oberholzer J, Bucher P, et al.: Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. *Diabetes* 2003;52:726–733.
144. El-Assaad W, Buteau J, Peyot ML, et al.: Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. *Endocrinology* 2003;144:4154–4163.
145. Clark A, Saad MF, Nezzet T, et al.: Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. *Diabetologia* 1990; 33:285–289.
146. Bell ET: Hyalinization of the islets of Langerhans in nondiabetic individuals. *American Journal of Pathology* 1959;35:801–805.
147. Hull RL, Jaikaran ETAS, Serpell LC, et al.: Human pro-islet amyloid polypeptide forms amyloid-like fibrils in vitro and could promote amyloidosis in diabetes. In: Kyle RA, Gertz MA (eds.) *Amyloid and Amyloidosis* 1998. New York, NY: Parthenon, 1999, pp. 542–544.
148. Krampert M, Bernhagen J, Schmucker J, et al.: Amyloidogenicity of recombinant human pro-islet amyloid polypeptide (ProIAPP). *Chemistry & Biology* 2000;7:855–871.
149. Marzban L, Rhodes CJ, Steiner DF, et al.: Impaired NH₂-terminal processing of human proislet amyloid polypeptide by the prohormone convertase PC2 leads to amyloid formation and cell death. *Diabetes* 2006;55:2192–2201.
150. Castillo GM, Cummings JA, Yang WH, et al.: Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation. *Diabetes* 1998;47:612–620.
151. Hull RL, Zraika S, Udayasankar J, et al.: Inhibition of glycosaminoglycan synthesis and protein glycosylation with WAS-406 and azaserine result in reduced islet amyloid formation in vitro. *American Journal of Physiology - Cell Physiology* 2007;293:C1586–C1593.
152. Meng F, Raleigh DP: Inhibition of glycosaminoglycan-mediated amyloid formation by islet amyloid polypeptide and proIAPP processing intermediates. *Journal of Molecular Biology* 2011;406: 491–502.
153. Hull RL, Peters MJ, Perigo SP, et al.: Overall sulfation of heparan sulfate from pancreatic islet beta-TC3 cells increases maximal fibril formation but does not determine binding to the amyloidogenic peptide islet amyloid polypeptide. *The Journal of Biological Chemistry* 2012;287:37154–37164.
154. Westermark P, Grimelius L: The pancreatic islet cells in insular amyloidosis in human diabetic and non-diabetic adults. *Acta Pathologica et Microbiologica Scandinavica* 1973;81:291–300.
155. Zraika S, Hull RL, Udayasankar J, et al.: Glucose- and time dependence of islet amyloid formation in vitro. *Biochemical and Biophysical Research Communications* 2007;354:234–239.
156. Marzban L, Tomas A, Becker TC, et al.: Small interfering RNA mediated suppression of pro-islet amyloid polypeptide expression inhibits islet amyloid formation and enhances survival of human islets in culture. *Diabetes* 2008;57:3045–3055.
157. Zraika S, Hull RL, Udayasankar J, et al.: Oxidative stress is induced by islet amyloid formation and time-dependently mediates amyloid-induced beta cell apoptosis. *Diabetologia* 2009;52:626–635.

158. Potter KJ, Scrocchi LA, Warnock GL, et al.: Amyloid inhibitors enhance survival of cultured human islets. *Biochimica et Biophysica Acta* 2009;1790:566–574.
159. de Koning EJP, Morris ER, Hofhuis FMA, et al.: Intracellular and extracellular amyloid fibrils are formed in cultured pancreatic-islets of transgenic mice expressing human islet amyloid polypeptide. *PNAS* 1994;91:8467–8471.
160. MacArthur DL, de Koning EJ, Verbeek JS, et al.: Amyloid fibril formation is progressive and correlates with beta-cell secretion in transgenic mouse isolated islets. *Diabetologia* 1999;42:1219–1227.
161. Park YJ, Lee S, Kieffer TJ, et al.: Deletion of Fas protects islet beta cells from cytotoxic effects of human islet amyloid polypeptide. *Diabetologia* 2012;55:1035–1047.
162. Subramanian SL, Hull RL, Zraika S, et al.: cJUN N-terminal kinase (JNK) activation mediates islet amyloid-induced beta cell apoptosis in cultured human islet amyloid polypeptide transgenic mouse islets. *Diabetologia* 2012;55:166–174.
163. Zraika S, Aston-Mourney K, Marek P, et al.: Neprilysin impedes islet amyloid formation by inhibition of fibril formation rather than peptide degradation. *The Journal of Biological Chemistry* 2010;285:18177–18183.
164. Huang CJ, Haataja L, Gurlo T, et al.: Induction of endoplasmic reticulum stress-induced β -cell apoptosis and accumulation of polyubiquitinated proteins by human islet amyloid polypeptide. *American Journal of Physiology - Endocrinology and Metabolism* 2007;293:E1656–E1662.
165. Huang CJ, Lin CY, Haataja L, et al.: High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. *Diabetes* 2007;56:2016–2027.
166. Hull RL, Zraika S, Udayasankar J, et al.: Amyloid formation in human IAPP transgenic mouse islets and pancreas, and human pancreas, is not associated with endoplasmic reticulum stress. *Diabetologia* 2009;52:1102–1111.
167. Masters SL, Dunne A, Subramanian SL, et al.: Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1 β in type 2 diabetes. *Nature Immunology* 2010;11:897–904.
168. Westwell-Roper C, Dai DL, Soukhatcheva G, et al.: IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction. *Journal of Immunology* 2011;187:2755–2765.
169. Cnop M, Welsh N, Jonas JC, et al.: Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. *Diabetes* 2005;54(S2):S97–S107.
170. Amyot J, Semache M, Ferdaoussi M, et al.: Lipopolysaccharides impair insulin gene expression in isolated islets of Langerhans via toll-like receptor-4 and NF-kappaB signalling. *PLoS ONE* 2012;7:e36200.
171. Eguchi K, Manabe I, Oishi-Tanaka Y, et al.: Saturated fatty acid and TLR signaling link beta cell dysfunction and islet inflammation. *Cell Metabolism* 2012;15:518–533.